NEW ZEALAND DATA SHEET

1 PRODUCT NAME (strength, pharmaceutical form)

ADACEL® 0.5 mL suspension for injection vial.
Pertussis Vaccine-Acellular Combined with Diphtheria and Tetanus Toxoids (Adsorbed).

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 0.5 mL dose of ADACEL contains:

- 2.5 mcg pertussis toxoid
- 5 mcg pertussis filamentous haemagglutinin
- 5 mcg pertussis fimbriae types 2 and 3
- 3 mcg pertussis pertactin
- ≥ 2 IU (2 LfU) diphtheria toxoid
- ≥ 20 IU (5 LfU)* tetanus toxoid
- 1.5 mg aluminium phosphate (equivalent to 0.33mg aluminium)
- 0.6% v/v phenoxyethanol
- ≤ 0.005mg formaldehyde
- ≤ 0.02mg glutaraldehyde
- water for injections to 0.5mL

*The formulated content of 5LfU per 0.5mL dose of tetanus toxoid is the same as the related product Tripacel®.

The vaccine is prepared from: adsorbed purified and formaldehyde detoxified diphtheria and tetanus toxins; adsorbed purified and glutaraldehyde detoxified pertussis toxin (pertussis toxoid or PT); adsorbed purified and formaldehyde treated filamentous haemagglutinin (FHA); adsorbed purified pertactin (PRN) and fimbriae types 2 and 3 (FIM).

ADACEL is an adult/adolescent formulation diphtheria-tetanus-acellular pertussis (dTpa) combination vaccine with reduced content of pertussis toxoid, filamentous haemagglutinin and diphtheria toxoid compared to paediatric diphtheria-tetanus-acellular pertussis (DTaP) formulations.

The manufacture of this product includes exposure to bovine materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product.

3 PHARMACEUTICAL FORM

ADACEL is a sterile, uniform, cloudy, white suspension for injection.
4 CLINICAL PARTICULARS

4.1 Therapeutic indications

ADACEL is indicated for active immunisation against tetanus, diphtheria and pertussis in persons aged 10 years and over as a booster following primary immunisation.

4.2 Dose and method of administration

The same dosage, a single 0.5 mL dose, applies to all age groups.

Booster doses of ADACEL should be given according to the current New Zealand immunisation guidelines.

Individuals with an incomplete, or no, history of a primary series of diphtheria and tetanus toxoids should not be vaccinated with ADACEL. A booster response will only be elicited in individuals who have been previously primed by vaccination.

The vaccine’s normal appearance is a uniform, cloudy, white suspension which may sediment during storage. Shake the vial well to uniformly distribute the suspension before withdrawing the dose.

Parenteral biological products should be inspected visually for extraneous particulate matter and/or discoloration prior to administration. If these conditions exist, the product should not be administered.

When administering a dose from a stoppered vial, do not remove either the stopper or the metal seal holding it in place. Once the vial has been opened, any of its contents not used immediately should be discarded. Aseptic technique must be used for withdrawal of the dose. Before injection, the skin over the site should be cleansed with a suitable germicide.

ADACEL should be administered intramuscularly. The preferred site is into the deltoid muscle. The intravascular or subcutaneous routes should not be used (for exception, see under 4.4 Special warnings and precautions for use).

After insertion of the needle, ensure that the needle has not entered a blood vessel.

ADACEL must not be mixed in the same syringe with other vaccines or other parenterally administered drugs or co-administered in the same syringe.

Product is for single use in one patient on one occasion only. Discard any residue.

4.3 Contraindications

ADACEL should not be administered to individuals who have previously had a hypersensitivity reaction to any vaccine containing diphtheria or tetanus toxoids, or pertussis (acellular or whole cell).
ADACEL should not be administered to individuals known to be hypersensitive to any component of the vaccine (see components listed in 2. QUALITATIVE AND QUANTITATIVE COMPOSITION) or residues carried over from manufacture (such as formaldehyde and glutaraldehyde).

ADACEL should not be administered to subjects who experienced an encephalopathy of unknown origin within 7 days of previous immunisation with a pertussis-containing vaccine, or to subjects who have experienced other neurological complications following previous immunisation with any of the antigens in ADACEL.

4.4 Special warnings and precautions for use

The use of ADACEL as a primary series, or to complete the primary series, has not been studied. A booster response will only be elicited in individuals who have been previously primed by vaccination. Individuals with an incomplete, or no, history of a primary series of diphtheria and tetanus toxoids should not be vaccinated with ADACEL.

Diphtheria and tetanus toxoid containing vaccines should be avoided in persons who have received a booster with a vaccine containing these toxoids within the previous five years because of the potential increased frequency of local adverse reactions.

There are currently no data upon which to base a recommendation for the optimal interval for administering subsequent booster doses with ADACEL to maintain antibody levels against pertussis. There are no data on the duration of protection against pertussis following vaccination with ADACEL.

As with all injectable vaccines, appropriate medical treatment and supervision should be readily available for immediate use in case of a rare anaphylactic reaction following the administration of vaccine. As a precautionary measure, adrenaline injection (1:1,000) must be immediately available in case of unexpected anaphylactic or serious allergic reactions.

The vaccine must be given intramuscularly, as subcutaneous administration increases the chances of a local reaction. Do not administer by intravascular injection. A persistent nodule at the site of injection may occur with all adsorbed vaccines particularly if administered into the superficial layers of the subcutaneous tissue.

Intramuscular injections should be given with care in patients suffering from coagulation disorders because of the risk of haemorrhage. In these situations administration of ADACEL by deep subcutaneous injection may be considered, although there is a risk of increased local reactions.

ADACEL should not be administered into the buttocks due to the varying amounts of fatty tissue in this region, nor by the intradermal route, since these methods of administration may induce a weaker immune response.

Formaldehyde and glutaraldehyde have been used in the manufacturing process of this product and trace residual amounts may be present in the final product. Therefore, a hypersensitivity reaction may occur.
If Guillain-Barré syndrome or brachial neuritis has occurred following receipt of prior vaccine containing tetanus toxoid, the decision to give any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks.

ADACEL should not be administered to individuals with progressive or unstable neurological disorders, uncontrolled epilepsy or progressive encephalopathy until a treatment regimen has been established, the condition has stabilised and the benefit clearly outweighs the risk.

The immunogenicity of the vaccine could be reduced by immunosuppressive treatment or immunodeficiency. It is recommended to postpone the vaccination until the end of such disease or treatment if practical.

Nevertheless, vaccination of HIV infected subjects or subjects with chronic immunodeficiency, such as AIDS, is recommended even if the antibody response might be limited.

As with any vaccine, immunisation with ADACEL may not protect 100% of susceptible individuals.

Vaccination should be deferred in the presence of any acute illness, including febrile illness. A minor afebrile illness such as mild upper respiratory infection is not usually a reason to defer immunisation.

Carcinogenicity, mutagenicity

ADACEL has not been evaluated for carcinogenicity or mutagenicity.

Paediatric population

ADACEL should not be used for primary immunisation.

ADACEL is indicated for use in children aged 10 years and over.

4.5 Interaction with other medicines and other forms of interaction

ADACEL can be administered concomitantly with Hepatitis B vaccine, using a separate limb for the site of injection. Concomitant administration of other vaccines with ADACEL has not been studied.

In the case of immunosuppressive therapy, refer to 4.4 Special warnings and precautions for use.

4.6 Fertility, pregnancy and lactation

Use in pregnancy (Category B2)

The effect of ADACEL on the development of the embryo and foetus has not been assessed. Vaccination in pregnancy is not recommended unless there is a definite risk of acquiring pertussis. As the vaccine is detoxified, risk to the embryo or the foetus is highly improbable. The benefits versus the risks of administering ADACEL in pregnancy should carefully be evaluated when there
is a high probable risk of exposure to a household contact or during an outbreak in the community.

Breastfeeding

The effect of administration of ADACEL during lactation has not been assessed. As ADACEL is detoxified; any risk to the mother or the infant is highly improbable. The benefits versus the risks of administering ADACEL during lactation should carefully be evaluated by the health-care provider, particularly when there is a high probable risk of disease transmission through exposure to a household contact, or during an outbreak in the community. The risks of disease transmission from the infected mother to the infant who may not have been fully immunised should also be evaluated.

Fertility

ADACEL has not been evaluated for impairment of fertility.

4.7 Effects on ability to drive and use machines

Not relevant.

4.8 Undesirable effects

The reactions are listed within body systems and categorised by frequency according to the following definitions:

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common</td>
<td>(≥ 1/10)</td>
</tr>
<tr>
<td>Common</td>
<td>(&lt;1/10 and ≥ 1/100)</td>
</tr>
<tr>
<td>Uncommon</td>
<td>(&lt;1/100 and ≥ 1/1,000)</td>
</tr>
</tbody>
</table>

Clinical Trial Experience

In clinical studies with 324 adolescents and 638 adults given ADACEL, the most frequently reported adverse reactions occurring during the first 24 hours included the following:

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Adverse Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common</td>
<td>Pain, swelling, redness at the injection site</td>
</tr>
<tr>
<td></td>
<td>Headache, decreased energy, generalised body-ache</td>
</tr>
<tr>
<td>Common</td>
<td>Fever, chills, nausea, diarrhoea, sore or swollen joints</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Vomiting</td>
</tr>
</tbody>
</table>

A causal relationship to vaccination was not established in all cases. All adverse reactions were generally mild and transient in duration. Fever was reported in less than 3% of vaccinees. There were no reports of fever over 39.9°C. This adverse reaction profile was shown to be comparable to that seen in vaccinees who received a booster with Td adsorbed vaccine (tetanus (5 LfU) and diphtheria (2 LfU) toxoids adsorbed). Late-onset local adverse reactions (i.e. a local adverse
reaction which had an onset or increase in severity 3 to 8 days post-immunisation) such as redness, swelling and pain, occurred in less than 2%.

The following table summarises Adverse Events (%) in ADACEL (dTpa) recipients 0 - 24 hours post vaccination:

<table>
<thead>
<tr>
<th>Event</th>
<th>ADOLESCENTS**</th>
<th>ADULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TC9704</td>
<td>TD9805</td>
</tr>
<tr>
<td></td>
<td>dTpa</td>
<td>dTpa</td>
</tr>
<tr>
<td>Local Reactions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Redness</td>
<td>8.5</td>
<td>9.6</td>
</tr>
<tr>
<td>Swelling</td>
<td>18.6</td>
<td>15.6</td>
</tr>
<tr>
<td>Pain</td>
<td>94.9</td>
<td>69.6</td>
</tr>
<tr>
<td>Systemic Reactions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever*</td>
<td>5.1</td>
<td>0.7</td>
</tr>
<tr>
<td>Headache</td>
<td>37.3</td>
<td>28.1</td>
</tr>
<tr>
<td>Chills</td>
<td>15.3</td>
<td>12.6</td>
</tr>
<tr>
<td>Body ache</td>
<td>15.3</td>
<td>18.5</td>
</tr>
<tr>
<td>Tiredness</td>
<td>23.7</td>
<td>37.0</td>
</tr>
<tr>
<td>Sore Joints</td>
<td>3.4</td>
<td>19.3</td>
</tr>
<tr>
<td>Nausea</td>
<td>6.8</td>
<td>12.6</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1.7</td>
<td>0.0</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1.7</td>
<td>4.4</td>
</tr>
</tbody>
</table>

* Includes fever ≥ 37.5°C and ≥ 39.1°C
** 12 - 18 years of age in TC9704 and 11-12 years of age in TD9805
*** >19 years of age
§ Includes (N=20) adolescents

Post-marketing Experience

In addition to the data from clinical studies, the following adverse events have been reported during the commercial use of ADACEL. All the adverse events have been very rarely reported (<0.01%); however, the exact incidence rates cannot precisely be calculated. This computation is based on the number of adverse events reported per estimated number of vaccinated patients.

Immune system disorders:

Hypersensitivity (anaphylactic) reaction (angioedema, oedema, rash, hypotension)

Nervous system disorders:

Paraesthesia, hypoesthesia, Guillain-Barré syndrome, brachial neuritis, facial palsy, convulsion, syncope, myelitis
Metabolism and Nutrition Disorders:
  Anorexia

Cardiac Disorders:
  Myocarditis

Skin and subcutaneous tissue disorders:
  Pruritus, urticaria

Musculoskeletal and Connective Tissue Disorders:
  Myositis, myalgia

General disorders and administration site conditions:
  Large injection site reactions (> 50 mm) and extensive limb swelling from the injection site beyond one or both joints occur after administration of ADACEL in adolescents and adults. These reactions usually start within 24 - 72 hours after vaccination, may be associated with erythema, warmth, tenderness or pain at the injection site and resolve spontaneously within 3 - 5 days.
  Injection site bruising, sterile abscess
  Underarm lymph node swelling

Potential Adverse Events

Other adverse events not listed above have been reported with other similar vaccines and should be considered potential adverse reactions to ADACEL. Although rarely, severe local reactions such as whole arm swelling following adsorbed tetanus vaccine has occurred and may be associated with high levels of antitoxin resulting from over-immunisation.

In addition, neurological conditions including peripheral neuropathies and demyelinating diseases of the central nervous system have been reported in temporal association with some tetanus or tetanus and diphtheria toxoid-containing vaccines.

Clinical data for use of ADACEL in individuals who have only received DTaP vaccines for priming in infancy and early childhood are currently not available.

Very rarely, large local reactions, consisting of redness and/or swelling > 50mm, some with circumferential swelling of the injected limb, have been reported following the fourth and fifth paediatric doses of some acellular pertussis-containing vaccine.

4.9 Overdose

Not applicable.
5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Pertussis, purified antigen, combinations with toxoids, ATC code: J07AJ52

Clinical efficacy and safety

A total of 962 individuals (324 adolescents and 638 adults), who had not been immunised against tetanus, diphtheria, or pertussis within the previous five years, received a single 0.5 mL dose of ADACEL in three clinical trials (TC9704, TD9805 and TC9707).

In TC9704, 449 (55 adolescents 12 to 17 years of age and 394 adults 18 to 54 years of age) received three lots of ADACEL (dTpa), while 300 (37 adolescents and 263 adults) were given a single 0.5 mL dose with an adult formulation diphtheria-tetanus vaccine (Td) and a monovalent acellular Pertussis (aP) vaccine, given separately, one month apart. In TD9805, 269 adolescents 11 to 12 years of age were vaccinated: 135 received ADACEL given alone followed by the first dose of a 3-dose primary series with Hepatitis B vaccine (HB), one month later, and 134 were given ADACEL concurrently with the first dose of HB.

In TC9704, the safety and immunogenicity profile of ADACEL was shown to be comparable to that observed with a single booster dose of Td and aP containing the same amount of tetanus and diphtheria toxoids and pertussis antigens, administered separately. In TD9805, the safety and immunogenicity of concomitant administration of Hepatitis B vaccine with ADACEL (dTpa+HB) was comparable to that observed with ADACEL alone. Antibody responses observed in adolescents and adults from TD9805 and TC9704 are presented in the tables below:

<table>
<thead>
<tr>
<th>Antitoxin</th>
<th>Vaccine</th>
<th>N</th>
<th>GMC</th>
<th>% ≥ 0.10 IU/mL</th>
<th>Antitoxin</th>
<th>Vaccine</th>
<th>N</th>
<th>GMC</th>
<th>% ≥ 0.10 IU/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetanus</td>
<td>dTpa</td>
<td>118</td>
<td>28.6</td>
<td>100.0</td>
<td>dTpa</td>
<td>446</td>
<td>15.7</td>
<td>100.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>dTpa+HB</td>
<td>129</td>
<td>26.1</td>
<td>100.0</td>
<td>Td</td>
<td>151</td>
<td>16.0</td>
<td>99.3</td>
<td></td>
</tr>
<tr>
<td>Diphtheria</td>
<td>dTpa</td>
<td>118</td>
<td>8.4</td>
<td>100.0</td>
<td>dTpa</td>
<td>446</td>
<td>0.8</td>
<td>85.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>dTpa+HB</td>
<td>129</td>
<td>6.8</td>
<td>100.0</td>
<td>Td</td>
<td>151</td>
<td>1.2</td>
<td>89.4</td>
<td></td>
</tr>
</tbody>
</table>

* Tetanus and diphtheria antitoxin levels were measured in EU and IU/mL, respectively

<table>
<thead>
<tr>
<th>Pertussis Antibody</th>
<th>Vaccine</th>
<th>N</th>
<th>GMC**</th>
<th>Pertussis Antibody</th>
<th>Vaccine</th>
<th>N</th>
<th>GMC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-PT</td>
<td>dTpa</td>
<td>118</td>
<td>169</td>
<td>Anti-PT</td>
<td>dTpa</td>
<td>445</td>
<td>144</td>
</tr>
<tr>
<td></td>
<td>dTpa+HB</td>
<td>129</td>
<td>144</td>
<td></td>
<td>aP</td>
<td>149</td>
<td>191</td>
</tr>
<tr>
<td>Anti-FHA</td>
<td>dTpa</td>
<td>118</td>
<td>445</td>
<td></td>
<td>dTpa</td>
<td>446</td>
<td>328</td>
</tr>
</tbody>
</table>
In TD9707, 244 adults (19 to 60 years of age) received ADACEL, while 126 received Td and aP, given separately, one month apart. The safety and immunogenicity profile of ADACEL was also shown to be comparable to that observed with a single booster dose of Td and aP in study TD9707.

The mechanism of protection from *B pertussis* disease is not well understood. In a pertussis efficacy trial conducted in Sweden between 1992 and 1995, primary immunisation with Sanofi Pasteur Limited’s acellular pertussis infant DTaP formulation conferred a protective efficacy of 85% against typical pertussis disease (WHO definition). Although ADACEL contains only one quarter of the amount of pertussis toxoid present in this acellular pertussis infant DTaP formulation, the antibody responses to ADACEL were superior to those observed in the pertussis efficacy trial.

### 5.2 Pharmacokinetic properties

Not relevant.

### 5.3 Preclinical safety data

Not applicable.

### 6 PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients

ADACEL contains aluminium phosphate, phenoxyethanol, formaldehyde, glutaraldehyde and water for injections as excipients.

#### 6.2 Incompatibilities

Not applicable.

#### 6.3 Shelf life

36 months from date of manufacture.
6.4 Special precautions for storage

Store at 2º to 8ºC. REFRIGERATE. DO NOT FREEZE. Do not use after expiry date.

6.5 Nature and contents of container

ADACEL is supplied as a single dose (0.5 mL) in a 2 mL glass vial in packs containing 1 vial and in packs containing 5 vials (5’s not currently marketed).

6.6 Special precautions for disposal

Any unused medicine or waste material should be disposed of in accordance with local requirements.

7 MEDICINE SCHEDULE

Prescription Medicine

8 SPONSOR

Australia
sanofi-aventis australia pty ltd
Building D, 12-24 Talavera Road
Macquarie Park NSW 2113
Australia
Tel: 1800 829 468

New Zealand
sanofi-aventis new zealand pty ltd
Level 8
56 Cawley St
Ellerslie
Auckland
New Zealand
Tel: 0800 727 838
9    DATE OF FIRST APPROVAL
31 May 2007

10   DATE OF REVISION OF THE TEXT
4 January 2017